First siRNA library screening in hard-to-transfect HUVEC cells by Zumbansen, Markus et al.
354 
 
©The Authors | Journal of RNAi and Gene Silencing | May 2010 | Vol 6, No 1 | 354-360 | OPEN ACCESS 
TECHNOLOGY REPORT  
 
 
First siRNA library screening in hard-to-transfect HUVEC cells 
 
Markus Zumbansen
1, Ludger M Altrogge
1, Nicole UE Spottke
1, Sonja Spicker
1, Sheila M Offizier
1, 
Sandra BS Domzalski
1, Allison L St Amand
2, Andrea Toell
1, Devin Leake
2 and Herbert A Mueller-
Hartmann
1* 
 
1Lonza Cologne AG, Nattermannallee 1, 50829 Cologne, Germany, 
2Thermo Fisher Scientific, Dharmacon Products, 
2650 Crescent Drive, #100, Lafayette, CO 80026, USA 
 
*Correspondence to: Herbert Mueller-Hartmann, Email: Herbert.Mueller-Hartmann@lonza.com, Tel: +49 221 991 
99347, Fax: +49 221 991 99199 
 
Received 26 March 2009; Revised 16 September 2009; Accepted 23 September 2009; Published online 29 October 2009 
 
J RNAi Gene Silencing (2010), 6(1), 354-360 
 
© Copyright The Authors: This is an open access article, published under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/). This license permits non-
commercial use, distribution and reproduction of the article, provided the original work is appropriately acknowledged 
with correct citation details. 
 
ABSTRACT 
 
Meaningful RNAi-based data for target gene identification are strongly dependent on the use of a 
biologically relevant cell type and efficient delivery of highly functional siRNA reagents into the selected 
cell type. Here we report the use of the Amaxa
® Nucleofector
® 96-well Shuttle
® System for siRNA screening 
in primary cells. Lonza’s Clonetics
® HUVEC-Human Umbilical Vein Endothelial Cells were transfected 
with Thermo Scientific Dharmacon siGENOME
® siRNA Libraries targeting protein kinases and cell cycle 
related genes and screened for genes important for cell viability. Of the 37 primary hits, down-regulation of 
33 led to reduced proliferation or increased cell death, while down-regulation of two allowed for better cell 
viability. The validated four genes out of the 16 strongest primary hits (COPB2, PYCS, CDK4 and MYC) 
influenced cell proliferation to varying degrees, reflecting differing importance for survival of HUVEC cells. 
Our results demonstrate that the Nucleofector
® 96-well Shuttle
® System allows the delivery of siRNA 
libraries in cell types previously considered to be difficult to transfect. Thus, identification and validation of 
gene targets can now be conducted in primary cells, as the selection of cell types is not limited to those 
accessible by lipid-mediated transfection. 
 
KEYWORDS: Nucleofection, RNAi, siRNA, primary cell, screening, transfection, HUVEC 
 
 
INTRODUCTION 
 
RNAi-based library screening has become a powerful in 
vitro tool to identify drug targets that play a role in 
disease development and progression (Martin and 
Caplen, 2007). Successful screening experiments using 
siRNA require efficient delivery of highly functional and 
specific siRNA molecules into appropriate cells. While 
lipid-mediated transfection is a common approach for 
siRNA delivery, many cell types, including suspension 
cell lines and primary cells, are not compatible with this 
technology (Merkerova et al, 2007). This limitation 
prevents analysis of many biologically relevant cell types 
and restricts siRNA library screenings mainly to 
transformed, adherent cells that often exhibit phenotypic 
and genetic anomalies after extended periods of culturing 
lines (MacKeigan et al, 2005; Bartz et al, 2006; 
Whitehurst et al, 2007). Ideally, the diversity of 
biological questions requires the use of appropriate cell 
types, typically primary cells. In addition to this issue, 
several of the lipid delivery reagents can cause 
cytotoxicity and are capable of inducing a potent 
interferon response and/or altering gene expression 
profiles (Marques and Williams, 2005; Fedorov et al, 
2005 ; Wang, 2006). These unintended phenotypes can 
significantly affect experimental outcomes and 
drastically interfere with identifying relevant genes and 
understanding a gene’s function. Human Umbilical Vein 355 
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Endothelial Cells (HUVEC), a difficult-to-transfect cell 
type, were screened with an siRNA library delivered 
using the Amaxa
® Nucleofector
® 96-well Shuttle
® 
System. The screen targeted protein kinases and genes 
associated with the cell cycle to identify target genes 
important for cell viability. 
 
MATERIALS AND METHODS 
 
The siRNA reagents used were Dharmacon Human 
siGENOME
® SMARTpool
® siRNA Libraries for Protein 
Kinases (targeting 779 genes) and Cell Cycle Regulation 
(targeting 111 genes) (Thermo Fisher Scientific).   
Clonetics
® HUVEC Cells (Lonza) were cultured in 
Clonetics
® EGM
® Endothelial Growth Medium (Lonza) at 
37
oC, 5% (v/v) CO2 and transfected according to the 
recommendations in the respective Optimized Protocol for 
96-well Nucleofection
® (Amaxa). Briefly, 2 x 10
4 HUVEC 
cells were transfected with 20 pmol siRNA (if not noted 
differently). For optimal assay conditions, post-
transfection HUVEC cells were plated in 96-well culture 
plates at a density of 2 x 10
3 cells per well (100 μl). Outer 
wells of culture plates were filled with media only in order 
to avoid edge effects in the phenotypic assays. HUVEC 
cells were analyzed 72 hrs post-transfection for cell 
viability. The QuantiGene
® Branched DNA Assay 
(Panomics) was utilized to quantify transcript levels and 
correlate target knockdown with biological phenotype. 
Cyclophilin B served as reference mRNA and values were 
normalized to samples transfected with control siRNA. For 
the primary screen (n=3 independent experiments), 
Clonetics
® HUVEC cells were transfected with the 
respective libraries or control siRNAs and analyzed for 
phenotypic effects (cell viability). Data from each screen 
were analyzed by statistical means: the Z’ factors (Zhang 
et al, 1999) of controls were determined to evaluate the 
quality of the experiment and robust Z-score calculation 
(Chung et al, 2008) was used for hit identification. For 
target validation, selected hits were first re-evaluated with 
a higher number of samples using the siRNA utilized in 
the primary screen. Samples were randomly arranged 
across the plate to ensure independence of the phenotype 
from well positions. Subsequently, hits were further 
validated by demonstrating multiple knockdown reagents 
in different formats induced the same phenotypes (e.g., 
single or specificity-enhanced Thermo Scientific 
Dharmacon ON-TARGETplus siRNA Reagents). 
 
RESULTS AND DISCUSSION 
 
Viability assay optimization 
For the kinase and cell cycle screen in HUVEC Cells, 
siRNA reagents targeting polo-like kinase 1 (PLK-1) and 
Cell Cycle Check-point Kinase 1 (CHK-1 or CHEK-1) 
were selected as positive controls to set up the viability 
assay. PLK-1 is a key regulator of mitotic progression in 
mammalian cells and the knock-down of PLK-1 is known 
to induce apoptosis in cancer cells (Spänkuch-Schmitt et 
al, 2002; Reagan-Shaw and Ahmad, 2005). CHEK-1 is 
involved in the DNA damage response and is also required 
for cell proliferation and survival. CHEK-1 knockdown by 
siRNA has been reported to induce mitotic arrest (Tang et 
al, 2006). As such, down-regulation of PLK-1 and/or 
CHEK-1 is expected to decrease cell viability. Using PLK-
1, post-transfection plating densities were adjusted to 
allow for significant discrimination of positive and 
negative control samples on the phenotypic level. This was 
achieved by plating HUVEC cells at a low cell density of 
2 x 10
3 per well for 3-4 days after transfection (Figure 
1A). As shown in Figure 1B, the phenotypic effect for 
PLK-1 silencing was weaker and built up slower than 
silencing of CHEK-1, thus representing potential 
differences expected for “strong” and “weak” library 
targets. It has been reported earlier that PLK-1 depletion 
by siRNA transfection exerts a strong effect on cancer cell 
lines, but not primary cells (Spänkuch-Schmitt et al, 2002; 
Reagan-Shaw and Ahmad, 2005). However, as the down-
regulation of PLK-1 mRNA was not demonstrated in the 
previous reports, it could not be excluded that the 
underlying cause was more of an issue of inefficient 
transfection of the siRNA rather than the significance of 
PLK-1 roles in cell survival in primary cells. Nevertheless, 
despite a PLK-1 mRNA knockdown of more than 90% 
(data not shown), cell survival of HUVEC cells was 
diminished only to approximately 50% after 96 hrs, 
suggesting that persistent PLK-1 may indeed be a factor in 
survivability of cancer cells. An analysis time point of 72 
hrs suited well for both targets. In pilot screens for further 
determination of assay robustness, controls were plated into 
the central 60 wells of a 96-well culture plate and analyzed 
for cell viability. Wells in the outer rows were filled with 
medium to avoid potential edge effects. Z’ factors of both 
positive controls (CHEK-1: 0.55; PLK-1: 0.22; Figure 1C; 
data for PLK-1 not shown) reflected a suitable window for 
discrimination of potential hits with different phenotypic 
strength in the subsequent screen from background. 
 
Primary screen and hit validation 
HUVEC Cells were transfected with siRNA pools 
targeting individual genes in the Human siGENOME
® 
siRNA Libraries for protein kinases and cell cycle 
regulation. Multiple independent screening experiments 
(n=3) were performed to confirm the reproducibility of 
individual primary hits. Robust Z-score for cell viability 
was calculated for each of the 890 targets in the three 
independent experiments. As an example, the robust Z-
scores of one screening experiment are shown in Figure 
2A. A substantial proportion of targets displayed a median 
absolute deviation (MAD) below -3 or above 3 (MAD >3) 
including our positive controls PLK-1 and CHEK-1, which 
are members of both libraries. Thirty-five targets plus 
CHEK-1 and PLK-1 had a mean MAD greater than 3 in 
the three screening experiments and thus were considered 
as potential hits (Figure 2F). Eighteen of these targets 
showed a robust phenotype with MAD of greater than 3 in 
all three screening experiments (Figure 2B), while 24 
targets were significant in two of the three experiments 
(Figure 2C) and 123 targets showed MAD greater than 3 
in just one experiment (Figure 2D). The remaining 725 
targets showed no response beyond the threshold in any 
experiment. The categories of targets with one or two 
experiments with MAD greater than 3 showed the highest 
standard deviations due to the occurrence of outliers. 
These categories also contained targets with a small 
standard deviation, suggesting that their importance for 
survival of  HUVEC  was  not  sufficiently  strong for the  356 
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Figure 1. Determination of optimal assay conditions. In three independent experiments, HUVEC cells were transfected with 20 pmol 
SMARTpool
® siRNA targeting PLK-1 (A, B) or CHEK-1 (B, C) and siGENOME
® non-targeting control. Cell viability was analyzed 
at different time points post Nucleofection
® (A/B: 24, 48, 72 and 96 hrs; C: 72 hrs). Values were normalized to the negative control 
samples (A, B) or to untreated cells (C). The rightmost dots in C represents the mean and SD of the 60 individual values. 
 
 
chosen assay conditions (Figure 2B and C). Every sixth 
target fell into these categories of unclear importance, thus 
five of six targets were reproducibly classified as either 
important or not relevant for survival of HUVEC (Figure 
2C and D). Generally, a considerable degree of variation 
was seen in the data, including the most significant hit 
category (Figure 2B).  The most striking examples were 
MYC, which nevertheless could be validated, and 
CHEK1, which was a member of the library and also 
served as a positive control (Figure 2B and F). The 
degree of data variation might be attributed to not fully 
standardized cell culture conditions during the 
preparation of the experiments and thus argues for our 
strategy to select the primary hits from repeated 
screening experiments. As a consequence, we chose all 
35 primary hits despite their standard deviation for 
further validation experiments. While a higher number of 
primary hits for validation lowered the probability for 
erroneously classified false negatives, it also lowered the 
validation rate. Of the 35 identified primary hits, 33 had 
a pro-proliferative/anti-apoptotic function, as their down-
regulation led to increased cell death, while 2 had an 
anti-proliferate effect as their knockdown allowed for 
better cell viability. The 16 strongest of the 33 pro-
proliferative hits plus the two positive controls were 
selected for further evaluation (Table 1).  
 
Five of the 18 selected targets (COPB2, CDK4, PYCS, 
MYC and PLK-1) were validated by demonstrating that 
the phenotype could be reproduced with multiple 
individual siGENOME
® siRNAs from the original 
SMARTpool
® and further with different siRNAs, i.e., an 
ON-TARGETplus
® SMARTpoolV (Figure 3A, Table 1). 
The phenotypes could be correlated to the knockdown on 
mRNA level (Figure 3B) and to the amount of 
transfected siRNA (Figure 3C; only COPB2 shown). 
Both results, redundant phenotypic effects with an 
alternative siRNA pool and linking these phenotypes to 
proven specific mRNA knockdown, suggest that these 
were not off-target effects. 
 
The reduction in cell survival with the ON-TARGETplus
® 
SMARTpool
® was mostly comparable to the corresponding 
siGENOME
® SMARTpool
®, but weaker than the strongest 
single siGENOME
® siRNAs (Figure 3A and B). In the case 
of CDK4, the phenotypic effect of the ON-TARGETplus
® 
SMARTpool
® was comparable to siGENOME
® siRNA 
duplex 4 despite a lower knock-down of the target mRNA 
(Figure 3A and B). For siRNAs of the same type, e.g., 
siGENOME
® siRNAs, the phenotypic effects correlated 
well with the observed knock-down efficiencies (Figure 3A 
and B). Six of the 18 selected targets were confirmed with 
two of four single siGENOME
® siRNAs, three of which 
could not be confirmed with the ON-TARGETplus
® 
SMARTpool
®, still suggesting them as potential hits that 
require further efforts for validation, such as expanding the 
set of tested single siRNAs. As discussed above for ON-
TARGETplus
®  siRNAs, the insufficient phenotypic effect 
of the siRNAs, which could not be validated, may be 
explained by lower knock-down efficiencies or the 
reduction of off-target effects that contributed to the overall 
phenotype. 357 
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Figure 2. Primary Screen. HUVEC cells were transfected with 20 pmol of the combined Human siARRAY
® SMARTpool
® siRNA 
Libraries for Kinases (targeting 779 genes) and Cell Cycle Regulators (targeting 111 genes). Cell viability was analyzed 72 hrs post- 
Nucleofection
®. (A) Representation of robust Z-scores of cell viability measures from 1 screening experiment. (B-E) Robust Z-scores 
of all primary hits with MAD of >3 in all three (B), two of three (C), or one of three (D) independent experiments and with MAD of 
<3 in all three experiments (E). (F) Robust Z-scores of the top 37 primary hits (with MAD of >3) from three independent 
experiments. 358 
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Figure 3. Hit validation. HUVEC cells were transfected with 20 pmol (if not indicated differently) siGENOME
® (siG) SMARTpool
® 
or single siRNA #1 - 4 (from the de-convoluted pool) targeting CDK4, COPB2, MYC or PYCS. CHEK-1 and siGENOME
® Non-
Targeting siRNA #1 (control siRNA) and siRNA targeting CHEK-1 (CHEK-1) served as controls. 72 hrs post- Nucleofection
® cell 
viability was analyzed and normalized to control the siRNA (A, C) and mRNA levels were determined for CDK4 (B) and COPB2 
(B, C) and normalized to cyclophilin B mRNA and the control siRNA. 
 
 
Five of the eighteen selected targets were considered 
“false positives”, because neither the ON-TARGETplus
® 
SMARTpool
®, nor more than one of four single siRNAs 
reproduced the phenotype seen with the original 
siGENOME
® SMARTpool
®. Thus, it is likely that these 
were the result of off-target effects of individual siRNA 
sequences. As for the above mentioned primary hits that 
showed a higher rate of validated single siRNAs, testing 
further single siRNAs with proven mRNA knockdown 
may allow a more definitive hit stratification. 
 
Previous reports demonstrate the involvement of most of 
the identified primary hits in cell cycle regulation, cell 
survival or apoptosis (Table 1). No such evidence could be 
found for the kinases IRAK3, considered as false positive, 
and RPS6KL1, which has been validated with two of four 
single siGENOME
® siRNAs. Hence, five of the classified 
“false positives” have been reported in earlier literature, 
but their importance for HUVEC cell survival and 
proliferation remain unclear. For a majority of the 
identified primary hits, earlier reports describe their 
importance for cancer cells, while little information is 
available with respect to primary cells. 
 
Cyclins, cyclin-dependent kinases and their substrates play 
pivotal roles during cell cycle progression and control 
proliferation of normal cells. Cyclin-dependent kinase 4 
(CDK4) phosphorylates retinoblastoma protein (Rb) and 
other Rb-related proteins (Ewen et al, 1993; Kato et al, 
1993; Leng et al, 2002) ultimately promoting the 
expression of various genes essential for cell cycle phase 
G1-S transition (Nevins, 2001). Low molecular-weight 
inhibitors of CDK4 lead to a delayed G2/M progression 
with reduced cell growth and mitosis rates in a number of 
cell lines (Burgess et al, 2006). However, CDK4, as well 
as the functionally redundant CDK6 and the associated D-
type cyclins (D1, D2 and D3) are not essential for cell 
proliferation in mammalian cell types (Kozar and Sicinski, 
2005; Malumbres, 2004). This explains the moderate, 
albeit consistent, reduction in cell viability after CDK4 
knockdown in our experiments. Nevertheless, inhibitors 
specific for CDK4 and CDK6 can show significant 
antiproliferative activity against Rb-positive tumor cells 
(Fry, 2004). 
 
The proto-oncogene c-MYC has been intensively studied 
and its deregulation by various mitogens leads to the 
genesis of diverse human cancers (Oster, 2002). The gene 
product of c-MYC is a transcription factor, involved in the 
regulation of cell cycle related genes, such as CDK4 or 
Cyclin B1 (Menssen, 2002). While deregulation of c-MYC 
results in hyperproliferation, antisense oligo-mediated359 
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Table 1. Protein kinases and cell cycle regulators in HUVEC cells. Top hits were selected from the primary screen. Hits are shown in 
descending order of MADs. “k” indicates members of the siRNA library against kinases, “cc” indicates members of the siRNA 
library against cell cycle related genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
knockdown of c-MYC leads to growth inhibition, i.e., in 
human smooth muscle cells (Shi et al, 1993). The relevance 
of CDK4 and c-MYC for cell cycle progression has been 
evident from previous studies (Hermeking et al, 2000), but 
neither COPB2 nor PYCS have been directly related to cell 
cycle regulation or described as survival factors. 
 
COPB2 is a subunit of the so called “coatomer” complex, 
which is essential for budding of cargo vesicles at the 
endoplasmatic reticulum and recognition of transport signals 
present on their surface for travelling to the Golgi apparatus 
(Reviewed in: Béraud-Dufour and Balch, 2002; Bonifacino 
and Glick, 2004). A putative importance of COPB2 for cell 
survival and as a drug target is underlined by the fact that 
novel cancer drugs have been designed based on Brefeldin 
A, an inhibitor of ADP ribosylation factor (ARF), which is 
indispensable for the assembly of the coatomer complex. 
(Carew et al, 2006; Donaldson et al, 1991, 1992a, 1992b; 
Helms and Rothman, 1992; Orci et al, 1993). The severe 
effect of COPB2 down-regulation on proliferation of 
HUVEC cells underlines its importance for cell survival and 
as a promising drug target for anti-tumor reagents. 
 
PYCS is a mitochondrial enzyme pivotal for the synthesis of 
proline (Csukai et al, 1997). Reduction of proline content by 
over-expression of proline dehydrogenase leads to formation 
of reactive oxygen species and reduced cell viability in a 
number of cancer cell lines (Liu et al, 2006). Down-regulation 
of PYCS by siGENOME
® SMARTpool
® or single siRNAs 
consistently reduced HUVEC survival by some 40%, similar 
to CHEK1, pointing towards PYCS as being important but 
not essential for cell survival (Figure 3A). 
CONCLUSIONS 
 
The presented  data demonstrate that the Nucleofector
® 
96-well Shuttle
® System allows the delivery of siRNA 
libraries, e.g., Dharmacon siGENOME
® Libraries, in cell 
types previously considered difficult to transfect. 
Preserved cell functionality and efficient mRNA 
knockdown allow the identification and validation of gene 
targets in primary cells, which reflect a higher biological 
relevance for certain pathways. 
 
Most of the identified and validated targets have been 
reported earlier to be implicated in the cell cycle, cell 
survival or apoptosis in cancer cells, while little has been 
known about their importance in normal primary cells. 
 
Our study suggests that overcoming the limitation of using 
transformed cell lines for functional screens and rather 
studying the relevant primary cells pledge the potential to 
identify novel drug target candidates. 
 
ACKNOWLEDGMENTS 
 
This work was funded by Lonza Cologne AG and Thermo 
Fisher Scientific, Dharmacon Products. 
 
COMPETING INTERESTS 
 
MZ, LMA NUES, SS, SMO, SBSD, AT and HAMH work 
for Lonza Cologne AG R&D. ASA and DL work for and/or 
have financial interests in Thermo Fisher Scientific. 360 
 
©The Authors | Journal of RNAi and Gene Silencing | May 2010 | Vol 6, No 1 | 354-360 | OPEN ACCESS 
REFERENCES 
 
Bartz SR, Zhang Z, Burchard J, et al. 2006. Small interfering RNA 
screens reveal enhanced cisplatin cytotoxicity in tumor cells having 
both BRCA network and TP53 disruptions. Mol Cell Biol, 26, 
9377-9386. 
Béraud-Dufour S and Balch W. 2002. A journey through the 
exocytic pathway. J Cell Sci ,115, 1779-1780. 
Bonifacino JS and Glick BS. 2004. The mechanisms of vesicle 
budding and fusion. Cell, 116, 153-166. 
Burgess A, Wigan M, Giles N, et al. 2006. Inhibition of S/G2 
phase CDK4 reduces mitotic fidelity. J Biol Chem, 281, 9987-
9995. 
Calvin S, Emch J, Wang et al. 2006. FuGENE
®HD Transfection 
Reagent: Choice of a Transfection Reagent with Minimal Off-
Target Effect as Analyzed by Microarray Transcriptional Profiling. 
Biochemica, 4, 22-25. 
Carew  JS, Nawrocki ST, Krupnik YV, et al. 2006. Targeting 
endoplasmic reticulum protein transport: a novel strategy to kill 
malignant B cells and overcome fludarabine resistance in CLL. 
Blood, 107, 222-231. 
Chung N, Locco L, Huff KW, et al. 2008. An efficient and fully 
automated high-throughput transfection method for genome-scale 
siRNA screens. J Biomol Screen, 13, 149-158. 
Csukai M, Chen CH, De Matteis MA, et al. 1997. The coatomer 
protein  β'-COP, a selective binding protein (RACK) for protein 
kinase Cε. J Biol Chem, 272, 29200-29206. 
Donaldson JG, Kahn RA, Lippincott-Schwartz J, et al. 1991. 
Binding of ARF and β-COP to Golgi membranes: possible 
regulation by a trimeric G protein. Science, 254, 1197-1199. 
Donaldson JG, Cassel D, Kahn RA, et al. 1992a. ADP-ribosylation 
factor, a small GTP-binding protein, is required for binding of the 
coatomer protein β-COP to Golgi membranes. Proc Nat Acad Sci 
USA, 89, 6408-6412. 
Donaldson JG, Finazzi D and Klausner RD. 1992b. Brefeldin A 
inhibits Golgi membrane-catalysed exchange of guanine nucleotide 
onto ARF protein. Nature, 360, 350-352. 
Emami KH, Brown LG, Pitts TE, et al. 2009. Nemo-like kinase 
induces apoptosis and inhibits androgen receptor signaling in 
prostate cancer cells. Prostate, 69, 1481-1492. 
Ewen ME, Sluss HK, Sherr CJ, et al. 1993. Functional interactions of 
the retinoblastoma protein with mammalian D-type cyclins. Cell, 
73, 487-497. 
Fedorov Y, King A, Anderson E, et al. 2005. Different delivery 
methods-different expression profiles. Nat Methods, 2, 241. 
Follenzi A, Bakovic S, Gual P, et al. 2000. Cross-talk between the 
proto-oncogenes Met and Ron. Oncogene, 19, 3041-3049. 
Fry DW, Harvey PJ, Keller PR, et al. 2004. Specific inhibition of 
cyclin-dependent kinase 4/6 by PD 0332991 and associated 
antitumor activity in human tumor xenografts. Mol Cancer Ther, 3, 
1427-1438. 
Helms JB and Rothman JE. 1992. Inhibition by brefeldin A of a 
Golgi membrane enzyme that catalyses exchange of guanine 
nucleotide bound to ARF. Nature, 360, 352-354. 
Hermeking H, Rago C, Schuhmacher M, et al. 2000. Identification of 
CDK4 as a target of c-MYC. Proc Nat Acad Sci USA, 97, 2229-
2234. 
Jaffe AB, Aspenström P, Hall A. 2004. Human CNK1 Acts as a 
Scaffold Protein, Linking Rho and Ras Signal Transduction 
Pathways. Mol Cell Biol 24, 1736-1746. 
Kamoun P, Aral B and Saudubray JM. 1998. A new inherited 
metabolic disease: delta1-pyrroline 5-carboxylate synthetase 
deficiency. Bull Acad Natl Med, 182, 131-137. 
Kato J, Matsushime H, Hiebert SW, et al. 1993. Direct binding of 
cyclin D to the retinoblastoma gene product (pRb) and pRb 
phosphorylation by the cyclin D-dependent kinase CDK4. Genes 
Dev, 7, 331-342. 
Kittler R, Putz G, Pelletier L, et al. 2004. An endoribonuclease-
prepared siRNA screen in human cells identifies genes essential for 
cell division. Nature, 432, 1036-1040. 
Kozar K and Sicinski P. 2005. Cell cycle progression without cyclin 
D-CDK4 and cyclin D-CDK6 complexes. Cell Cycle 4, 388-391. 
Leng X, Noble M, Adams PD, et al. 2002. Reversal of growth 
suppression by p107 via direct phosphorylation by cyclin 
D1/cyclin-dependent kinase 4. Mol Cell Biol, 22, 2242-2254. 
Line A, Slucka Z, Stengrevics A, et al. 2002. Characterisation of 
tumour-associated antigens in colon cancer. Cancer Immunol 
Immunother, 51, 574-582. 
Liu Y, Borchert GL, Surazynski A, et al. 2006. Proline oxidase 
activates both intrinsic and extrinsic pathways for apoptosis: the 
role of ROS/superoxides, NFAT and MEK/ERK signaling. 
Oncogene, 25, 5640-5647 
Malumbres M, Sotillo R, Santamaría D, et al. 2004. Mammalian 
cells cycle without the D-type cyclin-dependent kinases Cdk4 and 
Cdk6. Cell, 118, 493-504. 
Marques JT and Williams RG. 2005. Activation of the mammalian 
immune system by siRNAs. Nat Biotechnol, 23, 1399-1405. 
Martin SE and Caplen NJ. 2007. Applications of RNA interference in 
mammalian systems. Annu Rev Genomics Hum Genet, 8, 81-108. 
Menssen A and Hermeking H. 2002 Characterization of the c-MYC-
regulated transcriptome by SAGE: identification and analysis of c-
MYC target genes. Proc Nat Acad Sci USA, 99, 6274-6279. 
Merkerova M, Klamova H, Brdicka R, et al. 2007. Targeting of gene 
expression by siRNA in CML primary cells. Mol Biol Rep, 34, 27-
33. 
MacKeigan JP, Murphy LO and Blenis J. 2005. Sensitized RNAi 
screen of human kinases and phosphatases identifies new 
regulators of apoptosis and chemoresistance. Nat Cell Biol, 7, 591-
600. 
Müller J, Ory S, Copeland T, et al. 2001. C-TAK1 regulates Ras 
signaling by phosphorylating the MAPK scaffold, KSR1. Mol Cell, 
8, 983-993. 
Namkoong S, Kim CK, Cho YL, et al. 2009. Forskolin increases 
angiogenesis through the coordinated cross-talk of PKA-dependent 
VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling. 
Cell Signal, 21, 906-915. 
Nevins JR. 2001. The Rb/E2F pathway and cancer. Hum. Mol. 
Genet, 10, 699-703. 
Orci L, Palmer DJ, Ravazzola M, et al. 1993. Budding from Golgi 
membranes requires the coatomer complex of non-clathrin coat 
proteins. Nature, 362, 648-652. 
Oster SK, Ho CS, Soucie EL, et al. 2002. The myc oncogene: 
MarvelouslY Complex. Adv Cancer Res, 84, 81-154. 
Reagan-Shaw S and Ahmad N. 2005. Silencing of polo-like kinase 
(Plk) 1 via siRNA causes induction of apoptosis and impairment of 
mitosis machinery in human prostate cancer cells: implications for 
the treatment of prostate cancer. FASEB J, 19, 611-613. 
Shi Y, Hutchinson HG, Hall DJ, et al. 1993.  Downregulation of c-
myc expression by antisense oligonucleotides inhibits proliferation 
of human smooth muscle cells. Circulation, 88, 1190-1195. 
Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann, M et al. 2002. 
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis 
and spindle formation in human cancer cells. J Natl Cancer Inst, 94, 
1863-1877. 
Tang J, Erikson RL and Liu X. 2006. Checkpoint kinase 1 (Chk1) is 
required for mitotic progression through negative regulation of 
polo-like kinase 1 (Plk1). Proc Nat Acad Sci USA, 103, 11964-
11969. 
Whitehurst AW, Bodemann BO, Cardenas J, et al. 2007. Synthetic 
lethal screen identification of chemosensitizer loci in cancer cells. 
Nature, 446, 815-819. 
Zhang JH, Chung TD and Oldenburg KR. 1999. A Simple Statistical 
Parameter for Use in Evaluation and Validation of High 
Throughput Screening Assays. J Biomol Screen 4, 67-73. 
Yada Y, Higuchi K and Imokawa G. 1991. Effects of Endothelins on 
Signal Transduction and Proliferation in Human Melanocytes. J 
Biol Chem, 266, 18352-18357. 
Yalcin A, Clem BF, Simmons A, et al. 2009. Nuclear targeting of 6-
Phosphofructo-2-kinase (PFKFB3) increases proliferation via 
cyclin-dependent kinases. J Biol Chem, 284, 24223-24232. 